Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody KI-3 and the cytotoxic activity of KI-3 immunotoxin

International Journal of Cancer

Volumn 98, Issue 2, 2002, Pages 210-215

  Hansen, Hinrich P ^a,b   Matthey, Bärbel ^b   Barth, Stefan ^b   Kisseleva, Tatiana ^a   Mokros, Thilo ^a   Davies, Stephen J ^c   Beckett, R Paul ^c   Foelster Holst, Regina ^a   Lange, Hans H ^a   Engert, Andreas ^b   Lemke, Hilmar ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

CD30; Hydroxamate inhibitor; Immunotoxin; Internalization; Metalloproteinase

Indexed keywords

BATIMASTAT; BB 2116; CD30 ANTIGEN; HYDROXAMIC ACID; IMMUNOMODULATING AGENT; IMMUNOTOXIN; MARIMASTAT; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 3; N 1 (5 ACETYLAMINOMETHYLCARBAMOYLPENTYL) (2,2 DIMETHYLPROPYL) N 4 HYDROXY (4 HYDROXYPHENYLSULFANYLMETHYL)SUCCINAMIDE; RICIN A; SOLIMASTAT; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; IC 50; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REED STERNBERG CELL; TARGET CELL;

AMINOPYRIDINES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; HUMANS; HYDROXAMIC ACIDS; IMMUNOTOXINS; KINETICS; LYMPHOMA; LYMPHOMA, LARGE-CELL, KI-1; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0037051105     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10182     Document Type: Article

References (24)

1. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a sub-set of normal lymphoid cells
2. The expression of the Hodgkin'sdisease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Stemberg-Reed cells and histiocytic malignancies are derived from activated lymphoid cells
3. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen
4. Anti-CD30 antibody-based therapy
5. Development of immunotoxins for potential clinical use in Hodgkin's disease
6. Recombinant immunotoxins for the treatment of Hodgkin's disease
7. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma
8. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma
9. Ki-I (CD30) antigen is released by Ki-l-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay
10. Immunotoxins: Magic bullets or misguided missiles?
11. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies
12. CD30 shedding from karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme
13. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4)
14. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages
15. CD30 antigen in non-Hodgkin's lymphoma
16. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines
17. Cellular localizations and processing of the two molecular forms of the Hodgkin-associated Ki-1 (CD30) antigen. The protein kinase Ki-1/57 occurs in the nucleus
18. Membrane protein secretases
19. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPAinduced ectodomain shedding of membrane- anchored heparin-binding EGF-like growth factor
20. The ADAM gene family: Surface proteins with adhesion and protease activity
21. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage
22. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
23. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
24. Clinical studies with matrix metalloproteinase inhibitors